Clinical trials: Vector-Borne Diseases
Advanced Ovarian Cancer
Plasmodium Immunotherapy for Advanced Ovarian Cancer
The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer.
- Trial name
- NCT05924776
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Dengue
Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.
- Trial name
- NCT01477580
- Testing
- Low-dose V180 with low-dose ISCOMATRIX™ adjuvant, Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant, Medium-dose V180 (non-adjuvanted)
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Dengue Fever
IC14 in Adult Patients With Dengue Fever
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip…
- Trial name
- NCT03875560
- Testing
- IC14
- Sponsor
- Implicit Bioscience
Chikungunya Virus Infection
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.
- Trial name
- NCT03483961
- Testing
- CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted
- Where
- 3 sites in United States
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Human Immunodeficiency Virus (HIV) Infection
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
This is a study of HB-502 and HB-501 alternating 2-vector therapy in people living with human immunodeficiency virus (HIV) who are taking antiretroviral treatment (ART).
- Trial name
- NCT06430905
- Testing
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hookipa Biotech GmbH
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
This study aims to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for…
- Trial name
- KALUMA (NCT05842954)
- Testing
- KLU156, Coartem
- Where
- 33 sites in Burkina Faso, Côte d’Ivoire and 10 more
- Volunteers
- 1,720 people
- Sponsor
- Novartis Pharmaceuticals
Dengue
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model
- Trial name
- NCT05366439
- Testing
- AT-752
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Chagas Disease
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world.
- Trial name
- NuestroBen (NCT04897516)
- Testing
- Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole
- Where
- 6 sites in Argentina
- Volunteers
- 300 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
The purpose of this study is to determine the incidence of dengue fever and to build capacity for dengue vaccine trials in dengue-endemic regions of South Asia.
- Trial name
- NCT02570152
- Testing
- Blood sample collection
- Where
- Sri Lanka
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria Vaccine
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the…
- Trial name
- NCT07831226
- Testing
- LYB014 low dose, LYB014 high dose, LYB017 low dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Dengue Fever
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
- Trial name
- NCT02193087
- Testing
- TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized
- Where
- 7 sites in United States
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Takeda
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Lyme Disease
Novel Diagnostics for Early Lyme Disease
There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses.
- Trial name
- NCT03963635
- Testing
- MicroB-plex Lyme Immunoassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- MicroB-plex, Inc.
Tick-borne Encephalitis
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
The purpose of this study is to assess: TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT).
- Trial name
- NCT00161785
- Testing
- FSME-IMMUN 0.5ml
- Where
- 2 sites in Poland
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06977490
- Testing
- Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.), Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Encephalitis, Tick-Borne
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
The purpose of this study it is to evalutate the persistence of antibodies after a booster immunisation with a TBE vaccine for adults
- Trial name
- NCT00311493
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Novartis
Paludism
Evaluation of the STANDARD G6PD Rapid Test for Assaying the Enzymatic Activity of G6PD in French Guiana
In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatments against Plasmodium vivax malaria are: nivaquine for 3 days against circulating blood parasites and primaquine for 14…
- Trial name
- G6PD facile (NCT04698980)
- Testing
- blood samples (venous and capillary at the fingertip)
- Where
- French Guiana
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur